Skip to main content

Judd Wendell Moul, MD

James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine
Professor of Surgery
Professor in Anesthesiology
Office: 1573 White Zone, Duke South, Durham, NC 27710
Campus Mail: DUMC Box 3707 Med Ctr, Durham, NC 27710

Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center.  He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology.  He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009.  He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer.  He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World.  He is very committed to training residents and mentoring students and trainees. 

Education and Training

  • Fellowship, Urologic Oncology, Duke University, 1988 - 1989
  • Residency, Urology, Walter Reed Army Medical Center, 1983 - 1987
  • Residency, Surgery, Walter Reed Army Medical Center, 1982 - 1983
  • M.D., Thomas Jefferson University, 1982
  • B.S., Pennsylvania State University, 1979

Publications

Nelson, Joel B., Karim Fizazi, Kurt Miller, Celestia Higano, Judd W. Moul, Hideyuki Akaza, Thomas Morris, Stuart McIntosh, Kristine Pemberton, and Martin Gleave. “Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone..” Cancer 118, no. 22 (November 15, 2012): 5709–18. https://doi.org/10.1002/cncr.27674.

Full Text

Campbell, Lisa C., Francis J. Keefe, Daphne C. McKee, Sandra J. Waters, and Judd W. Moul. “Masculinity beliefs predict psychosocial functioning in African American prostate cancer survivors..” Am J Mens Health 6, no. 5 (September 2012): 400–408. https://doi.org/10.1177/1557988312450185.

Full Text

Djavan, Bob, James Eastham, Leonard Gomella, Bertrand Tombal, Samir Taneja, Seyed Saeid Dianat, Amir Kazzazi, et al. “Testosterone in prostate cancer: the Bethesda consensus..” Bju Int 110, no. 3 (August 2012): 344–52. https://doi.org/10.1111/j.1464-410X.2011.10719.x.

Full Text

Catalona, W. J., A. V. D’Amico, W. F. Fitzgibbons, O. Kosoko-Lasaki, S. W. Leslie, H. T. Lynch, J. W. Moul, M. S. Rendell, and P. C. Walsh. “What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation..” Annals of Internal Medicine 157, no. 2 (July 17, 2012): 137–38.

Scholars@Duke

Catalona, William J., Anthony V. D’Amico, William F. Fitzgibbons, Omofolasade Kosoko-Lasaki, Stephen W. Leslie, Henry T. Lynch, Judd W. Moul, Marc S. Rendell, and Patrick C. Walsh. “What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation..” Ann Intern Med 157, no. 2 (July 17, 2012): 137–38. https://doi.org/10.7326/0003-4819-157-2-201207170-00463.

Full Text

Yu, Evan Y., Kurt Miller, Joel Nelson, Martin Gleave, Karim Fizazi, Judd W. Moul, Faith E. Nathan, and Celestia S. Higano. “Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer..” J Urol 188, no. 1 (July 2012): 103–9. https://doi.org/10.1016/j.juro.2012.03.008.

Full Text

Moul, Judd W. “Minimally invasive open retropubic prostatectomy: in experienced hands--still the gold standard..” Oncology (Williston Park) 26, no. 7 (July 2012): 610–15.

Scholars@Duke

Moul, J. W. “Minimally invasive open retropubic prostatectomy: in experienced hands--still the gold standard..” Oncology (Williston Park, N.Y.) 26, no. 7 (July 1, 2012).

Scholars@Duke

Pages